Phaseline

Targets › FGF21R

FGF21R: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Jul 2028.

Open in Phaseline: the race on FGF21R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GSKEfimosfermin (BOS-580)
FGF21 receptor agonist
FGF21RPhase 2Metabolic Dysfunction-Associated SteatohepatitisJul 2028

Conditions

Metabolic Dysfunction-Associated Steatohepatitis (1)

Modalities

protein or peptide (1)

Companies

GSK (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.